Building A Wall? The Plan To End “March In” Threat To US Drug Patents

 
• By Michael McCaughan

Calls to exercise “march in” rights on federal patents licensed to pharmaceutical companies are a recurring theme in the US drug pricing debate. Now the Department of Commerce is proposing to make those threats even emptier than they already are.

Trumpet & Tuba Player
Pharma could soon be humming a happy tune about "march in" rights.

More from Pricing Debate

More from Market Access